Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EY: Don’t Expect Mega-Mergers To Return, But ‘Never Say Never’

EY Predicts Continued Emphasis On Bolt-On Deals, Partnerships In 2022

Executive Summary

Firm’s annual biopharma firepower report notes there were no mega-mergers in 2021 and the conditions continue to make smaller deals and partnerships a better risk proposition.

You may also be interested in...



Biopharma Has Money To Spend On M&A, EY Says – As Well As Need

Upcoming patent expirations are increasing the sector’s need to acquire candidates and products that can deliver near-term revenues, driving up valuations, EY’s 2024 Firepower report says.

M&A Has Been Down, But EY Argues Conditions Are Right For An Uptick In 2023

Despite concerns about the impact of the Inflation Reduction Act and constraining factors like inflation, EY believes more than $1.4tn in life sciences industry “firepower” should result in increased deal-making this year.

Are Market Conditions Setting Up A Biopharma M&A Wave?

A new EY report contends that declining biotech valuations and the need for large pharma to add pipeline assets may create conditions for a buyer’s market – although year-to-date M&A activity has been lackluster.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC145685

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel